Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) Publication of Research Note
London, New York, 21 September 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), is pleased to note the publication of a new analyst
Tiziana Life Sci PLC (TILS.L) Clinical Study with Nasally Administered Foralumab
Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
Tiziana Life Sci PLC (TILS.L) Demerger of StemPrintER and Distribution in Specie
Demerger of StemPrintER and Distribution in Specie Proposed capital reduction and notice of General Meeting
Tiziana Life Sci PLC (TILS.L) Patent Granted for Anti-IL-6/IL-6
Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for Covid-19 and other pulmonary diseases
Tiziana Life Sci PLC (TILS.L) Patent Granted for Foralumab
Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease
Tiziana Life Sci PLC (TILS.L) Update on Timings and Corporate Actions – Charting Update
New York/London, 30 July 2020 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and
Tiziana Life Sci PLC (TILS.L) Agreement with STC Biologics
Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19.